Compulsive features in behavioural addictions: The case of pathological gambling

Addiction

Volumn 107, Issue 10, 2012, Pages 1726-1734

  El Guebaly, Nady ^a   Mudry, Tanya ^b   Zohar, Joseph ^c   Tavares, Hermano ^d   Potenza, Marc N ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Compulsivity; Endophenotypes; Impulsivity; Pathological gambling

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NARCOTIC ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

BEHAVIOR THERAPY; CLASSIFICATION; COMPULSION; DIFFERENTIAL DIAGNOSIS; EGO; GENETIC PREDISPOSITION; HUMAN; METHODOLOGY; MOTIVATION; NERVE CELL NETWORK; PATHOLOGICAL GAMBLING; PHENOTYPE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

BEHAVIOR THERAPY; COMPULSIVE BEHAVIOR; DIAGNOSIS, DIFFERENTIAL; EGO; GAMBLING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOTIVATION; NARCOTIC ANTAGONISTS; NERVE NET; NEUROTRANSMITTER AGENTS; PHENOTYPE; SEROTONIN UPTAKE INHIBITORS;

EID: 84866041718     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03546.x     Document Type: Article

References (130)

1. Grant J. E., Potenza M. N., Weinstein A., Gorelick D. A. Introduction to behavioral addictions. Am J Drug Alcohol Abuse 2010; 35: 233-41.
2. Wareham J. D., Potenza M. N. Pathological gambling and substance use disorders. Am J Drug Alcohol Abuse 2000; 36: 242-7.
3. El-Guebaly N., Mudry T. Problematic internet use and the diagnostic journey. World Psychiatry 2010; 9: 93-4.
4. Holden C. Psychiatry. Behavioral addictions debut in proposed DSM-V. Science 2010; 327: 935.
5. American Psychiatric Association. DSM-5: The Future of Psychiatric Diagnosis. DSM-5 development website. 2010. Available at: http://www.dsm5.org/Pages/Default.aspx (accessed 15 July 2011). (Archived by Webcite at http://www.webcitation.org/60Cf7JKHc).
6. Hollander E., Benzaquen S. D. The obsessive-compulsive spectrum disorders. Int Rev Psychiatry 1997; 9: 99-110.
7. Lejoyeux M., Weinstein A. Compulsive buying. Am J Drug Alcohol Abuse 2010; 36: 248-53.
8. American Psychiatric Association. Diagnostic and Statistical Nanual of Mental Disorders, IV-TR edn. Arlington, VA: American Psychiatric Association; 2000.
9. Koob G. F., Volkow N. D. Neurocircuitry of addiction. Neuropharmacology 2010; 35: 217-38.
10. O'Brien C. P., Volkow N., Li T. K. What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006; 163: 764-5.
11. Holden C. 'Behavioral' addictions: do they exist? Science 2001; 294: 980-2.
12. Hollander E., Cohen L. J. Impulsivity and Compulsivity. Washington, DC: American Psychiatric Press; 1996.
13. Chamberlain S. R., Fineberg N. A., Blackwell A. D., Robbins T. W., Sahakian B. J. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry 2006; 163: 1282-4.
14. World Health Organization. International Classification of Diseases, 10th Revision. World Health Organization website. 2010. Available at: http://www.who.int/classifications/icd/en/ (accessed 15 July 2011). (Archived by Webcite at http://www.webcitation.org/60Cfqog86).
15. Rasmussen S. A., Eisen J. L. Epidemiological and clinical features of obsessive-compulsive disorder. In: Jenike M. A., Baer L. B., Minichielo W.E., editors. Obsessive-Compulsive Disorders: Theory and Management, 2nd edn. Chicago, IL: Year Book Medical; 1990, p. 39-60.
16. Koob G. F. Brain stress systems in the amygdala and addiction. Brain Res 2009; 1293: 61-75.
17. Everitt B., Robbins T. W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005; 8: 1481-9.
18. Zohar J., Fostick L., Juven-Wetzler E. Obsessive compulsive disorder. In: Belder M., Andreasen N., Lopez-Ibor J., Geddes J., editors. New Oxford Textbook of Psychiatry, 2nd edn. New York: Oxford University Press; 2009, p. 765-73.
19. Brewer J. A., Potenza M. N. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008; 75: 63-75.
20. Koob G. F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-8.
21. Koob G. F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97-129.
22. Potenza M. N., Koran L. M., Pallanti S. The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions. Psychiatry Res 2009; 170: 22-31.
23. de Castro V., Fong T., Rosenthal R. J., Tavares H. A comparison of craving and emotional states between pathological gamblers and alcoholics. Addict Behav 2007; 32: 1555-64.
24. Zohar J., Hollander E., Stein D. J., Westenberg H. G., The Cape Town Consensus Group. Consensus statement. CNS Spectr, Int J Neuropsychiatr Med 2007; 12: 59-63.
25. Blanco C., Moreyra P., Nunes E. V., Saiz-Ruiz J., Ibanez A. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry 2001; 6: 167-76.
26. Grant J. E., Brewer J. A., Potenza M. N. The neurobiology of substance and behavioral addictions. CNS Spectr 2006; 11: 924-30.
27. Robinson T. E., Berridge K. C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.
28. Fineberg N. A., Potenza M. N., Chamberlain S. R., Berlin H. A., Menzies L., Bechara A. etal. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 2010; 35: 591-604.
29. Chambers R. A., Taylor J. R., Potenza M. N. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003; 160: 1041-52.
30. Potenza M. N., Hollander E. Pathological gambling and impulse control disorders. In: Davis K. L., Charney D., Coyle J. T., Nemeroff C., editors. Neuropsychopharmacology: The 5th Generation of Progress. Baltimore, MD: Lippincott Williams and Wilkins; 2002, p. 1725-41.
31. Pauls D. L., Mundo E., Kennedy J. L. The pathophysiology and genetics of obsessive-compulsive disorder. In: Davis K., Charney D., Coyle J. T., Nemeroff C., editors. Neuropsychopharmacology: The 5th Generation of Progress. Baltimore, MD: Lippincott Williams and Wilkins; 2002, p. 1609-19.
32. Gross-Isseroff R., Cohen R., Sasson Y., Voet H., Zohar J. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 2004; 50: 200-5.
33. Denys D., de Geus F., van Megan H. J., Westenberg H. G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65: 1040-8.
34. Potenza M. N. Should addictive disorders include non-substance-related conditions? Addiction 2006; 101: 142-51.
35. Williams W. A., Potenza M. N. The neurobiology of impulse control disorders. Rev Bras Psiquiatr 2008; 30: S24-30.
36. Volkow N. D., Fowler J. S. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000; 10: 318-25.
37. van den Heuvel O. A., der Werf Y. D., Verhoef K. M., de Wit S., Berendse H. W., Wolters E. C. H. etal. Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J Neurol Sci 2010; 289: 55-9.
38. Leeman R. F., Potenza N. M. Impulse control disorders in Parkinson's disease: clinical characteristics and implications. Neuropsychiatry 2011; 1: 133-47.
39. Dalley J. W., Everitt B. J., Robbins T. W. Impulsivity, compulsivity, and top-down cognitive control. Neuron 2011; 69: 680-94.
40. Potenza M. N. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Phil Trans R Soc Lond B Biol Sci 2008; 363: 3181-9.
41. Reuter J., Raedler T., Rose M., Hand I., Glascher J., Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8: 147-8.
42. Wrase J., Kahnt T., Schlagenhauf F., Beck A., Cohen M. X., Knutson B. etal. Different neural systems adjust motor behavior in response to reward and punishment. Neuroimage 2007; 36: 1253-62.
43. Steeves T. D., Miyasaki J., Zurowski M., Lang A. E., Pellecchia G., VanEimeren T. etal. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009; 132: 1376-85.
44. Bradberry C. W. Cocaine sensitization and dopamine mediation of cue effects in rodents, monkeys, and humans: areas of agreement, disagreement, and implications for addiction. Psychopharmacology 2007; 191: 705-17.
45. Evans A. H., Pavese N., Lawrence A. D., Tai Y. F., Appel S., Doder M. etal. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-8.
46. Mataix-Cols D., van den Heuvel O. A. Common and distinct neural correlates of obsessive-compulsive disorder and related disorders. Psychiatr Clin North Am 2006; 29: 391-410.
47. Potenza M. N., Leung H. C., Blumberg H. P., Peterson B. S., Fulbright R. K., Lacadie C. M. etal. An fMRI stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003; 160: 1990-4.
48. Rosenthal R. J., Lesieur H. R. Self-reported withdrawal symptoms and pathological gambling. Am J Addict 1992; 1: 150-4.
49. Lightsey O. R., Hulsey C. D. Impulsivity, coping, stress, and problem gambling among university students. J Couns Psychol 2002; 49: 202-11.
50. Lubman D. I., Yucel M., Pantelis C. Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction 2004; 99: 1491-502.
51. Nordahl T. E., Benkelfat C., Semple W. E., Gross M., King A. C., Cohen R. M. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 1989; 2: 23-8.
52. Volkow N. D., Wang G.-J., Overall J. E., Hitzemann R., Fowler J. S., Pappas N. R. etal. Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification. Alcohol Clin Exp Res 1997; 21: 1278-84.
53. Maruff P., Purcell R., Pantelis C. Obsessive compulsive disorder. In: Harrison J. E., Owen A. M., editors. Cognitive Deficits in Brain Disorders. London: Martin Dunitz; 2002, p. 249-72.
54. Comings D. E. The molecular genetics of pathological gambling. CNS Spectr 1998; 3: 20-37.
55. Rodriguez-Jimenez R., Avila C., Ponce G., Ibanez M. I., Rubio G., Jimenez-Arriero M. A. etal. The Taq1A polymorphism linked to the DRD2 gene is related to lower attention and less inhibitory control in alcoholic patients. Eur Psychiatry 2006; 21: 66-9.
56. Lobo D. S., Souza R. P., Tong R. P., Casey D. M., Hodgins D. C., Smith G. J. etal. Association of functional variants in the dopamine D2- like receptors with risk for gambling behaviors in healthy Caucasian subjects. Biol Psychol 2010; 85: 33-7.
57. Ibanez A., Blanco C., de Castro I. P., Fernandez-Piqueras J., Saiz-Ruiz J. Genetics of pathological gambling. J Gambl Stud 2003; 19: 11-22.
58. Hemmings S. M. J., Stein D. J. The current status of association studies in obsessive-compulsive disorder. Psychiatr Clin North Am 2006; 29: 411-44.
59. Lochner C., Hemmings S. M. J., Kinnear C. J. D., Niehaus J., Nel D. G., Corfield V. A. etal. Cluster analysis of obsessive-compulsive spectrum disorder in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry 2005; 46: 14-9.
60. Baca-Garcia E., Salgado B. R., Segal H. D., Lorenzo C. V., Acosta M. N., Romero M. A. etal. A pilot genetic study of the continuum between compulsivity and impulsivity in females: the serotonin transporter promoter polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 713-7.
61. Gottesman II, Gould T. D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
62. Chamberlain S. R., Menzies L., Hampshire A., Suckling J., Fineberg N. A., del Campo N. etal. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008; 321: 421-2.
63. Chamberlain S. R., Fineberg N. A., Menzies L. A., Menzies L. A., Blackwell A. D., Bullmore E. T. etal. Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164: 335-8.
64. Menzies L., Achard S., Chamberlain S. R., Fineberg N., Chen C. H., del Campo N. etal. Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 2007; 130: 3223-36.
65. Anholt G. E., Emmelkamp P. M., Cath D. C., van Oppen P., Nelissen H., Smit J. H. Do patients with OCD and pathological gambling have similar dysfunctional cognitions. Behav Res Ther 2004; 42: 529-37.
66. Hollander E., Wong C. M. Body dysmorphic disorder, pathological gambling, and sexual compulsions. J Clin Psychiatry 1995; 56: 7-12.
67. Ettelt S., Ruhrmann S., Barnow S., Buthz F., Hochrein A., Meyer K. etal. Impulsiveness in obsessive-compulsive disorder: results from a family study. Acta Psychiatr Scand 2007; 115: 41-7.
68. Tavares H., Gentil V. Pathological gambling and obsessive-compulsive disorder: towards a spectrum of disorders of volition. Rev Bras Psiquiatr 2007; 29: 107-17.
69. Hollander E., Wong C. M. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56: 3-6.
70. Cavedini P., Riboldi G., Keller R., D'Annucci A., Bellodi L. Frontal lobe dysfunction in pathological gambling. Biol Psychiatry 2002; 51: 334-41.
71. Cavedini P., Riboldi G., D'Annucci A., Belotti P., Cisima M., Bellodi L. Decision making heterogeneity in obsessive-compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia 2002; 40: 205-11.
72. Bechara A. Risky business: emotion, decision-making, and addiction. J Gambl Stud 2003; 19: 23-51.
73. Chamberlain S. R., Fineberg N. A., Blackwell A. D., Clark L., Robbins T. W., Sahakian B. J. A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia 2007; 45: 654-62.
74. Watkins L. H., Sahakian B. J., Robertson M. M., Veale D. M., Rogers R. D., Pickard K. M. etal. Executive function in Tourette's syndrome and obsessive compulsive disorder. Psychol Med 2005; 35: 571-82.
75. Crockford D. N., El-Guebaly N. Psychiatric comorbidity in pathological gambling: a critical review. Can J Psychiatry 1998; 43: 43-50.
76. Potenza M. N. Impulse control disorders and co-occurring disorders: dual diagnosis considerations. J Dual Diagn 2007; 3: 47-57.
77. Potenza M. N., Xian H., Shah K., Scherrer J. F., Eisen S. A. Shared genetic contributions to pathological gambling and major depression in men. Arch Gen Psychiatry 2005; 62: 1015-21.
78. Petry N. M., Stinson F. S., Grant B. F. Co-morbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66: 564-74.
79. Cunningham-Williams R. M., Cottler L. B., Compton W. M. I., Spitznagel E. L. Taking chances: problem gamblers and mental health disorders: results from the St. Louis Epidemiologic Catchment Area study. Am J Public Health 1998; 88: 1093-6.
80. Ruscio A. M., Stein D. J., Chiu W. T., Kessler R. C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53-63.
81. Leung K. S., Cottler L. B. Treatment of pathological gambling. Curr Opin Psychiatry 2009; 22: 69-74.
82. Brewer J. A., Grant J. E., Potenza M. N. The treatment of pathological gambling. Addict Disord Treat 2008; 7: 1-14.
83. O'Malley S. S., Jaffe A. J., Chang G., Schottenfeld R. S., Meyer R. E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881-7.
84. Volpicelli J. R., Alterman A. I., Hayashida M., O'Brien C. P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80.
85. Grant J. E., Kim S. W., Hartman B. K. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008; 69: 783-9.
86. Grant J. E., Potenza M. N., Hollander E., Cunningham-Williams R., Nurminen T., Smits G. etal. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163: 303-12.
87. Kim S. W., Grant J. E., Adson D. E., Shin Y. C. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49: 914-21.
88. Grant J. E., Kim S. W., Hollander E., Potenza M. N. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) 2008; 200: 521-7.
89. Revital A., Leah F., Ari G., Joseph Z. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008; 18: 455-61.
90. Insel T. R., Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983; 140: 1219-20.
91. Keuler D. J., Altemus M., Michelson D., Greenberg B., Murphy D. L. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996; 40: 154-6.
92. Dannon P. N., Lowengrub K., Gonopolski Y., Musin E., Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28: 6-10.
93. Hollander E., Pallanti S., Allen A., Sood E., Baldini R. N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162: 137-45.
94. Pallanti S., Quercioli L., Sood E., Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63: 559-64.
95. McDougle C. J., Price L. H., Goodman W. K., Charney D. S., Heninger G. R. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175-84.
96. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006; 29: 553-84.
97. Grant J. E., Potenza M. N. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004; 16: 27-34.
98. Fong T., Kalechstein A., Bernhard B., Rosenthal R., Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008; 89: 298-303.
99. McElroy S. L., Nelson E. B., Welge J. A., Kaehler L., Keck P. E. Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008; 69: 433-40.
100. Zack M., Poulos C. X. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high versus low impulsivity. J Psychopharmacol 2009; 23: 660-71.
101. Hollander E., DeCaria C. M., Finkell J. N., Begaz T., Wong C. M., Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47: 813-7.
102. Kim S. W., Grant J. E., Adson D. E., Shin Y. C., Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002; 63: 501-7.
103. Blanco C., Petkova E., Ibáñez A., Sáiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002; 14: 9-15.
104. Grant J. E., Kim S. W., Potenza M. N., Blanco C., Ibanez A., Stevens L. etal. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 2003; 18: 243-9.
105. Grant J. E., Potenza M. N. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol 2006; 21: 203-9.
106. Hollander E., Kaplan A., Pallanti S. Pharmacological treatments. In: Grant J. E., Potenza M. N., editors. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Press; 2004, p. 189-206.
107. Blanco C., Potenza M. N., Kim S. W., Ibáñez A., Zaninelli R., Saiz-Ruiz J. etal. A pilot study of impulsivity and compulsivity in pathological gambling. Psychiatry Res 2009; 167: 161-8.
108. Potenza M. N., Sofuoglu M., Carroll K. M., Rounsaville B. J. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 2011; 69: 695-712.
109. Grant J. E., Kim S. W., Odlaug B. L. N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62: 652-75.
110. Kalivas P. W. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10: 561-72.
111. Grant J. E., Chamberlain S. R., Odlaug B. L., Potenza M. N., Kim S. W. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl 2010; 212: 603-12.
112. Miller W. R., Leckman A. L., Delaney H. D., Tinkcom M. Long-term follow-up of behavioral self-control training. J Stud Alcohol 1992; 53: 249-61.
113. Kadden R. M., Litt M. D., Cooney N. L., Busher D. A. Relationship between role-play measures of coping skills and alcoholism treatment outcome. Addict Behav 1992; 17: 425-37.
114. Sylvain C., Ladouceur R., Boisvert J. M. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol 1997; 65: 727-32.
115. Hodgins D. C., Currie S. R., El-Guebaly N. Motivational enhancement and self-help treatments for problem gambling. J Consult Clin Psychol 2001; 69: 50-7.
116. Petry N. M., Ammerman Y., Bohl J., Doersch A., Gay H., Kadden R. etal. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol 2006; 74: 555-67.
117. Grant J. E., Potenza M. N. Treatments for pathological gambling and other impulse control disorders. In: Gorman J., Nathan P., editors. A Guide to Treatments That Work. Oxford, UK: Oxford University Press; 2007, p. 561-77.
118. Petry N. M. Gamblers anonymous and cognitive-behavioral therapies for pathological gamblers. J Gambl Stud 2005; 21: 27-33.
119. Hohagen F., Winkelmann G., Rasche R., Hand I., Konig A., Munchau N. etal. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry 1998; 35: 71-8.
120. Neziroglu F., Henricksen J., Yaryura-Tobias J. A. Psychotherapy of obsessive-compulsive disorder and spectrum: established facts and advances, 1995-2005. Psychiatr Clin North Am 2006; 29: 585-604.
121. Battersby M. The South Australian Statewide Gambling Therapy Service: exposure as the model of therapy. Alberta Gaming Research Institute Conference, Banff, Alberta, 8-10 April 2010.
122. Oakes J., Battersby M. W., Pols R. G., Cromarty P. Exposure therapy for problem gambling via videoconferencing: a case report. J Gambl Stud 2008; 24: 107-18.
123. Grant J. E., Donahue C. B., Odlaug B. L., Kim S. W., Miller M. J., Petry N. M. Imaginal desensitisation plus motivational interviewing for pathological gambling: randomised controlled trial. Br J Psychiatry 2009; 195: 266-7.
124. Echeburua E., Baez C., Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in the psychological treatment of pathological gambling: long-term outcome. Behav Cogn Psychother 1996; 24: 51-72.
125. Fineberg N. A., Saxena S., Zohar J., Craig K. J. Obsessive-compulsive disorder: boundary issues. CNS Spectr 2007; 12: 359-75.
126. Voon V., Sohr M., Lang A. E., Potenza M. N., Siderowf A. D., Whetteckey J. etal. Impulse control disorders in parkinson disease: a multicenter case-control study. Ann Neurol 2011; 69: 1-11.
127. Milosevic A., Ledgerwood D. M. The subtyping of pathological gambling: a comprehensive review. Clin Psychol Rev 2010; 30: 988-98.
128. Ledgerwood D. M., Petry N. M. Subtyping pathological gamblers based on impulsivity, depression, and anxiety. Psychol Addict Behav 2010; 24: 680-8.
129. Meda S. A., Stevens M. C., Potenza M. N., Pittman B., Gueorguieva R., Andrews M. M. etal. Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol 2009; 20: 390-9.
130. Whiteside S. P., Lynam D. R., Miller J. D., Reynolds S. K. Validation of the UPPS impulsive behaviour scale: a four-factor model of impulsivity. Eur J Pers 2005; 19: 559-74.